Insulet to Preview New Clinical Data and Next Generation Omnipod® System at the American Diabetes Association’s 77th Scientific Sessions

Northwell Health Ranked Nation’s Top Health System for Diversity

New York State’s largest health care provider and private employer made the list for the ninth straight year and remained in the top spot in the 2021 DiversityInc rankings for Hospitals and Health Systems.

ZAP Surgical and Swiss Neuro Radiosurgery Center Announce Imminent Installation of New Gyroscopic Radiosurgery Platform for Treating Brain Tumors

ZAP-X is also the first and only dedicated radiosurgery system to no longer require Cobalt-60 radioactive sources, thus eliminating the significant costs to license, secure and regularly replace live radioactive isotopes.

Kathy Sherwood Joins Pelvital USA, Inc. Board of Directors

Sherwood's experience, which includes a diverse group of medical product companies such as Boston Scientific, American Medical Systems, St. Jude Medical, Kinetic Concepts, Transoma Medical and Medtronic, gives her an understanding of the problems faced by both large and small companies.

Insulet will exhibit at this year’s Scientific Session at Booth Location 507 and have four poster presentations to share new clinical data supporting the benefits of both its current Omnipod System, as well as its Omnipod Horizon Automated Glucose Control System.

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it will present new data for its Omnipod System including results from a hybrid closed-loop study utilizing the Omnipod Horizon™ Automated Glucose Control System (Omnipod Horizon System) involving a total of 24 pediatric patients from six to 18 years of age at the American Diabetes Association (ADA) 77th Scientific Sessions at the San Diego Convention Center June 9-13, 2017.

Shacey Petrovic, President and Chief Operating Officer, “We are deeply committed to delivering product innovation that provides our Podders with the technology and support they need to simplify their lives and ease the burden of diabetes. Petrovic went on to say, “With this compelling clinical data and groundbreaking new technology in development, we continue to provide our users and their health care providers with robust and simplified solutions to enhance quality of life and promote successful diabetes management.”

Dr. Bruce Buckingham, Professor of Pediatric Endocrinology at the Lucille Salter Packard Children’s Hospital, Stanford University, and Principal Investigator, will be presenting the hybrid closed-loop study outcomes.

Omnipod presentations at ADA include:

Poster Number & Title*

Date / PT


1744-P: Impact of the Omnipod Insulin Management System
on Glycemic Control: A Survey of the T1D Exchange Glu
Online Community

Saturday, June 10, 11:30 a.m. – 12:30 p.m. Poster Hall

132-LB: Safety and Feasibility of Omnipod Hybrid Closed-
Loop in Children Aged 6-12 Years with Type 1 Diabetes
Using a Personalized Model Predictive Control Algorithm

Sunday, June 11, 12:00 p.m. – 1:00 p.m. Poster Hall

1055-P: Safety and Feasibility of Omnipod Hybrid Closed
-Loop in Adolescents with Type 1 Diabetes Using a
Personalized Model Predictive Control Algorithm

Sunday, June 11, 12:00 p.m. – 1:00 p.m. Poster Hall

1423-P: A Quality Improvement Protocol Using Only
Tubeless Insulin Pumps for Treatment of Hospitalized
Children and Adolescents with Diabetes Mellitus

Monday, June 12, 12:00 p.m. – 1:00 p.m. Poster Hall

* Data subject to embargo until Saturday, June 10, 2017



Subscribe to Medical Device News Magazine here.

Related Articles